Sugi Predict

Sugi Predict / Compounds / SCHEMBL3035932

SCHEMBL3035932

SCHEMBL3035932

O=C(O)c1nc2cc([N+](=O)[O-])ccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.52
▸ MAPT P10636 6/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ POLB P06746 3/20 0.50
▸ PKM P14618 1/20 0.50
▸ NPY1R P25929 1/20 0.50
▸ NPY2R P49146 1/20 0.50
▸ PIN1 Q13526 2/20 0.48
▸ NPBWR1 P48145 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAOB P27338 1/20 0.45
▸ NOS1 P29475 1/20 0.45
▸ GRIA1 P42261 1/20 0.45
▸ GRIA2 P42262 1/20 0.45
▸ GRIA3 P42263 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27354737 0.89 ALDH1A1 (0.54) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL20495050 0.89 MMP2 (0.47) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL3935171 0.88 ALDH1A1 (0.61) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL3640534 0.88 ALDH1A1 (0.61) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL3055116 0.87 ALDH1A1 (0.51) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL30707882 0.87 ALDH1A1 (0.51) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL6324064 0.83 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL31154195 0.83 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL29086752 0.82 MEN1 (0.52) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL30912933 0.82 MEN1 (0.52) ALDH1A1MAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 — — CN disclosed
WO-2024219864-A1 NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF 주식회사 넷타겟 2024-10-24 — — WO disclosed
CN-117285439-A Phenylalanine amide derivatives as beta 2 Use of allosteric antagonists of adrenergic receptors 常州大学 2023-12-26 — — CN disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 — — CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 — — EP disclosed
CN-113943259-A Amino acid derivative, preparation method and application thereof 西安禾渼生物医药有限公司 2022-01-18 — — CN disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 — — WO disclosed
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 — — US disclosed
US-10266737-B2 Adsorption systems using metal-organic frameworks ARKEMA INC. (US) 2019-04-23 — — US disclosed
US-20150291870-A1 ADSORPTION SYSTEMS USING METAL-ORGANIC FRAMEWORKS ARKEMA INC. 2015-10-15 — — US disclosed
EP-2885365-A2 ADSORPTION SYSTEMS USING METAL-ORGANIC FRAMEWORKS Arkema, Inc. (US) 2015-06-24 — — EP disclosed
WO-2014028574-A9 ADSORPTION SYSTEMS USING METAL-ORGANIC FRAMEWORKS ARKEMA INC. (US) 2015-04-02 — — WO disclosed
WO-2014028574-A2 ADSORPTION SYSTEMS USING METAL-ORGANIC FRAMEWORKS ARKEMA INC. (US) 2014-02-20 — — WO disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 — — US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 — — US disclosed
EP-2046789-A2 LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-04-15 — — EP disclosed
EP-1389223-B1 METHOD FOR PRODUCING POLYISOCYANATES BAYER MATERIALSCIENCE AG (DE) 2008-07-23 — — EP disclosed
WO-2008012782-A2 LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-01-31 — — WO disclosed
US-7030266-B2 Method for producing polyisocyanates BAYER AKTIENGESELLSCHAFT (DE) 2006-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 ALDH1A1 2425/4885MAPT 3429/4885MEN1 3658/4885
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 ALDH1A1 348/4885MAPT 791/4885MEN1 3585/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A ALDH1A1 1646/4885MAPT 4514/4885MEN1 3206/4885
US-20150291870-A1 ADSORPTION SYSTEMS USING METAL-ORGANIC FRAMEWORKS PFAS, CHIA, PARN ALDH1A1 1737/4885MAPT 785/4885MEN1 1447/4885
US-10266737-B2 Adsorption systems using metal-organic frameworks PFAS, CHIA, PARN ALDH1A1 1737/4885MAPT 785/4885MEN1 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.